(Q38239573)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Filip K Knop

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Patrick Miossec

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Bjarne Due Larsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ulrich Werner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

14 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

1223-1251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119443%20AND%20SRC:MED&resulttype=core&format=json

Dysfunction of retinal neurons and glia during diabetes

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Diabetes, hyperglycaemia, and acute ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Associations between structural and functional changes to the kidney in diabetic humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Hyperglycaemia, diabetes and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Revisiting the links between glycaemia, diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Hypoglycemia in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Diabetes and protein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Prediabetes: evaluation of β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Hypoglycemia and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.942638